ReGenesys

Foundation date

17/10/2005

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

ReGenesys BV is a wholly-owned subsidiary of Athersys, Inc. (NASDAQ: ATHX), a biotechnology company in Cleveland, Ohio, U.S.A., that is developing MultiStem® cell therapy, a patented, adult-derived, “off-the-shelf” stem cell product initially for disease indications in the neurological, cardiovascular, inflammatory and immune areas.  Athersys has several ongoing clinical trials to evaluate its MultiStem product candidate.

Upcoming events

Latest news

  • Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

    13 hours ago

  • Indigo Diabetes announces first participant enrolled in the SHINE clinical trial

    Thursday September 29th 2022

  • FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome

    Tuesday September 27th 2022